Experienced in Visceromegaly

Dr. Reem Ghalib

Hepatology
Texas Digestive Disease Consultants, PLLC
1001 N Waldrop Dr, Suite 509, 
Arlington, TX 
Experienced in Visceromegaly
Texas Digestive Disease Consultants, PLLC
1001 N Waldrop Dr, Suite 509, 
Arlington, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Reem Ghalib is a Hepatologist in Arlington, Texas. Dr. Ghalib is rated as an Experienced provider by MediFind in the treatment of Visceromegaly. Her top areas of expertise are Nonalcoholic Steatohepatitis (NASH), Hepatitis C, Non-Alcoholic Fatty Liver Disease, and Hepatitis.

Her clinical research consists of co-authoring 23 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hepatology
Licenses
Internal Medicine in TX
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

TEXAS DIGESTIVE DISEASE CONSULTANTS, PLLC
1001 N Waldrop Dr, Suite 509, Arlington, TX 76012

Additional Areas of Focus

Dr. Ghalib has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2025
Intervention Type: Drug
Study Drug: HM15211
Study Phase: Phase 2
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
Enrollment Status: Active_not_recruiting
Publish Date: April 11, 2025
Intervention Type: Drug
Study Drug: Belapectin
Study Phase: Phase 2/Phase 3
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Obeticholic acid
Study Phase: Phase 3
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: September 16, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)
A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Enrollment Status: Completed
Publish Date: May 18, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Patient and Investigator Blinded, Placebo Controlled, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With Non-alcoholic Steatohepatitis (NASH)
A Randomized, Patient and Investigator Blinded, Placebo Controlled, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With Non-alcoholic Steatohepatitis (NASH)
Enrollment Status: Terminated
Publish Date: January 05, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)
Enrollment Status: Completed
Publish Date: September 16, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
Enrollment Status: Unknown
Publish Date: March 19, 2019
Intervention Type: Drug
Study Drug: Emricasan
Study Phase: Phase 2
View 8 Less Clinical Trials

23 Total Publications

High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence.
High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence.
Journal: The American journal of gastroenterology
Published: September 25, 2020
Similar Doctors
Distinguished in Visceromegaly
Dr. Apurva Modi
Hepatology
Distinguished in Visceromegaly
Dr. Apurva Modi
Hepatology

Healthtexas Provider Network

5408 Colleyville Blvd, 
Colleyville, TX 
 (9.8 miles away)
817-498-9920
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Apurva Modi is a Hepatologist in Colleyville, Texas. Dr. Modi is rated as a Distinguished provider by MediFind in the treatment of Visceromegaly. His top areas of expertise are Hepatitis, Hepatitis C, Visceromegaly, Cirrhosis, and Endoscopy.

Distinguished in Visceromegaly
Dr. Maisha Barnes
Hepatology
Distinguished in Visceromegaly
Dr. Maisha Barnes
Hepatology

MedHealth

1411 N Beckley Ave Pavilion III, Ste 268, 
Dallas, TX 
 (18.3 miles away)
972-449-0540
Experience:
21+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Maisha Barnes is a Hepatologist in Dallas, Texas. Dr. Barnes has been practicing medicine for over 21 years and is rated as a Distinguished provider by MediFind in the treatment of Visceromegaly. Her top areas of expertise are Hepatitis, Hepatitis C, Visceromegaly, Congenital Hepatic Fibrosis, and Liver Transplant.

Distinguished in Visceromegaly
Dr. Manjushree Gautam
Hepatology
Distinguished in Visceromegaly
Dr. Manjushree Gautam
Hepatology

Healthtexas Provider Network

1400 8th Ave, 
Fort Worth, TX 
 (13.3 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Manjushree Gautam is a Hepatologist in Fort Worth, Texas. Dr. Gautam is rated as a Distinguished provider by MediFind in the treatment of Visceromegaly. Her top areas of expertise are Hepatitis, Visceromegaly, Cirrhosis, Enlarged Liver, and Endoscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ghalib's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile